Human Leukocyte Antigen

Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment
Alice Newey, Beatrice Griffiths, Justine Michaux, Hui Song Pak, Brian J. Stevenson, Andrew Woolston, Maria Semiannikova, Georgia Spain, Louise J. Barber, Nik Matthews, Sheela Rao, David Watkins, Ian Chau, George Coukos, Julien Racle, David Gfeller, Naureen Starling, David Cunningham, Michal Bassani-Sternberg, Marco Gerlinger

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 309; DOI: 10.1186/s40425-019-0769-8
Cancer-specific T cell receptor isolation for cancer immunotherapy
Debbie Emma Baker, Linda Hibbert, Luise Weigand, Samantha Paston, Ruth Ryan, Zoe Donnellan, Ruth Simmons, Kathy Hale, Louise Conlon, Joseph Dukes, Vanessa Clark, Caroline Boudousquie, Giovanna Bossi, Emma Hickman, Alex Powlesland, Annelise Vuidepot, Namir Hassan, Bent Jakobsen

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P380; DOI: 10.1186/2051-1426-3-S2-P380
Novel and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3 K27M mutation
Yafei Hou, Gary Kohanbash, Kaori Okada, Shruti Shrivastav, Matthew Smith-Cohn, Theodore Nicolaides, Sabine Mueller, Angel Carcaboso, Ian Pollack, Hideho Okada

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P445; DOI: 10.1186/2051-1426-3-S2-P445
High-throughput characterization of the ovarian cancer HLA peptidome
Andrea Patterson, Wilfried Bardet, Curtis McMurtrey, Saghar Kaabinejadian, Ken Jackson, William Hildebrand

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P139; DOI: 10.1186/2051-1426-2-S3-P139
Novel therapeutic and diagnostic antibodies against KIR3DL2, a unique tumor antigen overexpressed on subtypes of T cell lymphomas
Anne Marie-Cardine, Nicolas Viaud, Arnaud Dujardin, Joly Rachel, Nathalie Granier, Laurent Gauthier, Cecile Bonnafous, Mathieu Blery, Carine Paturel, Armand Bensussan, Martine Bagot, Helene Sicard

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P45; DOI: 10.1186/2051-1426-1-S1-P45
Direct analysis of HLA/HER-2 peptide epitopes
Andrea Patterson, Wilfried Bardet, Ken Jackson, Jon Weidanz, William Hildebrand

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P62; DOI: 10.1186/2051-1426-1-S1-P62
P69. Targeting naturally presented, leukemia-derived HLA ligands with TCR-transgenic T cells for the treatment of therapy refractory leukemias
K Richard, S Schober, M Rami, S Mall, J Merl, J Slotta-Huspenina, S Stevanovic, DH Busch, C Peschel, AM Krackhardt

Journal for ImmunoTherapy of Cancer Mar 2014, 2 (Suppl 2) P43; DOI: 10.1186/2051-1426-2-S2-P43
S78. Proffered paper: High-affinity CD20-specific TCRs suitable for adoptive immunotherapy can be readily isolated from the allo-repertoire using reverse immunology
L Jahn, P Hombrink, C Hassan, MGD Kester, MP Schoonakker, JHF Falkenburg, P van Veelen, MHM Heemskerk

Journal for ImmunoTherapy of Cancer Mar 2014, 2 (Suppl 2) I16; DOI: 10.1186/2051-1426-2-S2-I16

Log in using your username and password

Main menu

Log in using your username and password

You are here

Human Leukocyte Antigen